{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/management/moderate-eczema/","result":{"pageContext":{"chapter":{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema","depth":2,"htmlHeader":"<!-- begin field ed056b2d-a12e-40e9-ba1d-8924a9af8db1 --><h2>Scenario: Moderate eczema</h2><!-- end field ed056b2d-a12e-40e9-ba1d-8924a9af8db1 -->","summary":"Covers the management of a person with areas of dry skin, frequent itching, and redness (with or without excoriation and localized skin thickening).","htmlStringContent":"<!-- begin item 833a8f59-c6d1-476e-a632-528c4644a089 --><!-- begin field 1a4d1888-d52a-4089-9f8b-acbd00858155 --><p>From age 1 month onwards.</p><!-- end field 1a4d1888-d52a-4089-9f8b-acbd00858155 --><!-- end item 833a8f59-c6d1-476e-a632-528c4644a089 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"5b4b963e-7bc2-5794-a6c0-6cdd00f3c036","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field c4fcde6b-5be1-4617-92bb-a7130128a7bb --><h3>How should I manage moderate eczema?</h3><!-- end field c4fcde6b-5be1-4617-92bb-a7130128a7bb -->","summary":null,"htmlStringContent":"<!-- begin item 86ddb764-dbb2-4197-bb4f-a7130128a640 --><!-- begin field 442ac38a-2afd-4c51-977b-a7130128a7bb --><p><strong>If a person presents with <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/assessment/#assessing-severity-of-atopic-eczema\">moderate eczema</a> (or an acute flare of moderate eczema):</strong></p><ul><li><strong>Consider the need for immediate admission or referral. </strong>For example:<ul><li>Admit to hospital if <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/background-information/complications/\">eczema herpeticum</a> (widespread herpes simplex virus) is suspected.</li></ul></li><li><strong>Consider the possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/background-information/causes/\">trigger factors</a></strong><strong> or <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/infected-eczema/#management\">infection</a></strong><strong>, </strong>which can precipitate or worsen a flare.</li><li><strong>Prescribe appropriate treatment.</strong><ul><li>Prescribe a generous amount of emollients, and advise frequent and liberal use (more than usual). For more information on emollients, including available products and usage instructions, see the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/\">Emollients</a>.</li><li><strong>If the skin is inflamed,</strong> prescribe a moderately potent topical corticosteroid (for example betamethasone valerate 0.025% or clobetasone butyrate 0.05%) to be used on inflamed areas. Treatment should be continued for 48 hours after the flare has been controlled. <ul><li>For delicate areas of skin (such as the face and flexures), consider starting with a mild potency topical corticosteroid (such as hydrocortisone 1%) and increase to a moderate potency corticosteroid only if necessary. Aim for a maximum of 5 days' use.</li><li>For more information on topical corticosteroids, including available products and usage instructions, see the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/\">Topical corticosteroids</a>.</li></ul></li><li>Occlusive dressings or dry bandages may be of benefit; however, treatment should only be started by a healthcare professional trained in their use (otherwise consider referral).</li><li><strong>If there is severe itch or urticaria,</strong> consider prescribing a one-month trial of a <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/oral-antihistamines/\">non-sedating&nbsp;antihistamine</a> (such as cetirizine, loratadine, or fexofenadine).</li><li><strong>If there are areas of infected skin, </strong>see <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/infected-eczema/\">Scenario: Infected eczema</a> for management information.</li></ul></li><li><strong>Prescribe preventative treatment according to the usual severity of the condition between flares.</strong><ul><li>Consider prescribing a maintenance regimen of topical corticosteroids to control areas of skin prone to frequent flares (not recommended for the face, genitals, or axillae). Options include a<strong> '</strong>step down approach' <em>or</em> 'intermittent treatment'. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#regimen-for-maintenance\">Maintenance regimens</a> for more information on these regimens.</li><li>Topical calcineurin inhibitors (tacrolimus and pimecrolimus) are a second-line option. However, they should only be prescribed by a specialist (including GPs with a specialist interest in dermatology).</li></ul></li><li><strong>Give appropriate information and advice, </strong>including general information on atopic eczema, measures to maintain the skin and reduce the risk of flares, self-care advice, and information on treatments not recommended. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/mild-eczema/#additional-information-advice\">Additional information and advice</a> for more information.</li><li><strong>Optimal follow up depends on a number of factors, </strong>such as the severity of the condition, the treatment the person is receiving, and their health and age (for instance, more frequent follow up will be needed in a small child receiving large quantities of moderately potent topical corticosteroids).<ul><li>Review emollient use on an annual basis to ensure optimal usage.</li><li>Topical corticosteroids require regular review if there is heavy usage; however, this is unlikely to be necessary with moderate eczema. Review <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#regimen-for-maintenance\">maintenance therapy</a> with topical corticosteroids at 3–6 months to assess effectiveness.</li><li>Review the use of non-sedating antihistamines every 3 months (treatment can be stopped, then restarted if symptoms worsen).</li></ul></li><li><strong>Refer f</strong><strong>or a routine dermatology appointment if:</strong><ul><li>The diagnosis is, or has become, uncertain.</li><li>Current management has not controlled eczema satisfactorily (for example the person is having one to two flares per month), or the person is reacting adversely to many emollients.</li><li>Facial eczema has not responded to appropriate treatment.</li><li>Treatment (application) advice is needed (for example bandaging techniques).</li><li>Contact allergic dermatitis is suspected (for example if there is persistent eczema or facial, eyelid, or hand eczema). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dermatitis-contact/\">Dermatitis - contact</a> for more information.</li><li>There is recurrent secondary infection.</li><li>Eczema is <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/assessment/#assessing-psychological-impact\">assessed</a> as causing significant social or psychological problems (for example sleep disturbance).</li></ul></li><li><strong>Refer to immunology, dermatology, or paediatrics if </strong>a food allergy is suspected and the expertise to diagnose and manage food allergy is not available in primary care. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/moderate-eczema/#breastfed-bottle-fed-infants\">Breastfed and bottle-fed infants</a> for more information.</li><li><strong>Refer to a clinical psychologist,</strong> people whose eczema is controlled but whose quality of life and psychological well-being have not improved (this may not be directly related to the severity of the eczema).</li></ul><!-- end field 442ac38a-2afd-4c51-977b-a7130128a7bb --><!-- end item 86ddb764-dbb2-4197-bb4f-a7130128a640 -->","subChapters":[{"id":"577e9df9-77ac-575b-bac8-2ea60031e96e","slug":"basis-for-recommendation-a21","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f394f4c5-5b25-4ad8-85bd-a7130128a7c0 --><h4>Basis for recommendation</h4><!-- end field f394f4c5-5b25-4ad8-85bd-a7130128a7c0 -->","summary":null,"htmlStringContent":"<!-- begin item a2157fe3-2f5a-4fee-b406-a7130128a7c0 --><!-- begin field 3ac7e6ac-246d-4436-9718-a7130128a7c0 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<em> </em>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults.</p><p>These recommendations are also in line with those in <em>Management of atopic eczema in primary care </em>published by the Scottish Intercollegiate Guideline Network (SIGN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>], <em>Caring for children and young people with atopic eczema: guidance for nurses</em> published by the Royal College of Nursing (RCN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>], <em>Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies </em>published by the<em> </em>American Academy of Dermatology (AAD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>], <em>Atopic eczema</em> published by the Primary Care Dermatology Society (PCDS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>], the<em> S2k guideline on diagnosis and treatment of atopic dermatitis - short version </em>(a German guideline<em> </em>supported financially by the<em> </em>German Dermatology Society [DDG]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>], the <em>ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients </em>published by the European Task Force on Atopic Dermatitis (ETFAD) and European Academy of Dermatology and Venerology (EADV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>]<em>, </em>and in review articles on atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Stein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>].</p><h5>Immediate admission</h5><ul><li>Eczema herpeticum is potentially life-threatening condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. If suspected, prompt emergency admission should be arranged for confirmation of the diagnosis and antiviral treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>].</li></ul><h5>Prescribing appropriate treatment</h5><ul><li>NICE recommends a stepped approach for managing atopic eczema. This means that treatment should be tailored to the severity of the eczema, and stepped up or down according to the severity of symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].</li><li><strong>Emollients</strong> are almost universally recommended as first-line treatment for atopic eczema, and experts advise that is should form the basis of management and should always be used, even when the skin is clear [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>].<ul><li>A Cochrane systematic review of 77 studies (n = 6603, mean age = 18.6 years, mean duration = 6.7 weeks) assessed the effects of moisturisers for eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">van Zuuren, 2017</a>].   <ul><li>The evidence suggested that most moisturisers showed some beneficial effects in prolonging time to flare, reducing the number of flares, and reducing the amount of topical corticosteroids needed to achieve similar reductions in eczema severity, producing better results when used with active treatment. However, there was no evidence that one moisturiser is better than another. </li><li>Adverse events reporting was limited (smarting, stinging, pruritus, erythema, and folliculitis).</li></ul></li></ul></li><li><strong>Topical corticosteroids</strong> are the most effective treatment to address the inflammatory component of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>], and there is reasonable evidence of benefit for their use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>].<ul><li>The potency of the topical steroid should be tailored to the severity of the eczema and the area of the skin being treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>].</li></ul></li><li><strong>Antihistamines</strong> are not recommended for routine use in the management of atopic eczema, as they have shown poor efficacy in controlling atopic eczema-associated itch [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>]. However, NICE recommends that a 1-month trial of a non-sedating antihistamine can be considered where there is severe itching or urticaria. If successful, the treatment can be continued, while symptoms persist, and should be reviewed every 3 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. This recommendation is based mainly on clinical experience, as there is only very limited evidence from controlled trials on the effectiveness of antihistamines for the treatment of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Hoare et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">National Collaborating Centre for Women's and Children's Health, 2007</a>].</li></ul><h5>Prescribing preventative treatment </h5><ul><li><strong>Topical corticosteroids</strong> should ideally be used only during flares of eczema. However, CKS recognizes that some people will require long-term management with a corticosteroid to control their condition.<ul><li><strong>The step down approach</strong> is not specifically recommended by NICE for the control of flares, but is implied in their clinical guideline. This requires the person to use the lowest amount and potency of corticosteroid to control eczema, in an attempt to minimize adverse effects. </li><li><strong>The intermittent treatment </strong>consists of two treatment options:<ul><li><strong>The twice weekly therapy</strong> is recommended in the SIGN guideline, which states that although constant use of topical corticosteroids is undesirable due to the risk of local and systemic adverse effects, twice weekly maintenance treatment with a topical corticosteroid should be considered in people with moderate to severe atopic eczema experiencing frequent relapses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>].</li><li><strong>The weekend therapy </strong>is recommended by NICE and may prevent flares occurring. There is good evidence from randomized controlled trials (RCTs) that intermittent treatment with a topical corticosteroid (on 2 or 3 consecutive days) can reduce flare recurrence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">National Collaborating Centre for Women's and Children's Health, 2007</a>].</li></ul></li><li>Expert opinion in a guideline is that the proactive, intermittent use of topical steroids as maintenance treatment (once or twice a week) on areas that commonly flare is useful to help prevent relapses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>].</li></ul></li><li><strong>Tacrolimus and pimecrolimus (topical calcineurin inhibitors)</strong> have been shown to be effective in the treatment of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>]. Following a Technology Appraisal on their use for atopic eczema, NICE concluded that they [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2004a</a>]:<ul><li>Are not recommended as first-line treatments for atopic eczema of any severity.</li><li>Should be initiated 'only by physicians (including general practitioners) with a special interest and experience in dermatology, and only after careful discussion with the person about the potential risks and benefits of all appropriate second-line treatment options'.</li></ul></li></ul><h5>Giving appropriate information and advice</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/mild-eczema/#additional-information-advice\">Additional information and advice</a> for more information.</li></ul><h5>Active follow up not required</h5><ul><li>Expert opinion in the PCDS guideline is that a follow-up appointment is a good opportunity to reinforce the continued need to practise good skin care, in particular to encourage the frequent and liberal use of emollients and to ensure that the treatment is suitable for the person [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]. The NICE Guideline Development Group (GDG) states that the repeat prescribing of emollients over long periods without review should be discouraged, and annual reviews should be carried out [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<ul><li>NICE does not make any recommendations on the optimal time for review of people using topical corticosteroids, but recommends that people should be referred if they are not responding adequately to treatment with topical corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].</li><li>NICE states that the weekend therapy should be reviewed within 3–6 months to assess effectiveness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. CKS has extrapolated this recommendation to the step down and the twice weekly regimens.</li></ul></li></ul><h5>Referral</h5><ul><li>The NICE GDG could not find any clinical evidence or evidence on cost-effectiveness in relation to referral and treatment outcomes for eczema. The GDG therefore based these recommendations on referral advice from other guidance and on the GDG's collective experience.<ul><li>The recommendations are also in line with recommendations in other guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>] on atopic eczema.</li></ul></li><li>Expert opinion in the NICE guideline <em>Food allergy in children and young people. Diagnosis and assessment of food allergy in children and young people in primary care and community settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2011b</a>] is that if a food allergy is suspected, a healthcare professional with the appropriate competencies should take an allergy-focused clinical history tailored to the presenting symptoms and age of the child or young person. Management will depend on the results of this. For more information, see the <a href=\"https://www.nice.org.uk/guidance/cg116/evidence/full-guideline-136470061\" data-hyperlink-id=\"908d24f3-b6ca-46c0-b4c5-a8f70154b899\">full NICE guideline</a>. </li></ul><!-- end field 3ac7e6ac-246d-4436-9718-a7130128a7c0 --><!-- end item a2157fe3-2f5a-4fee-b406-a7130128a7c0 -->","subChapters":[]}]},{"id":"e943d473-7339-577b-af0b-e56df28638bc","slug":"additional-information-advice","fullItemName":"Additional information and advice","depth":3,"htmlHeader":"<!-- begin field ff5ae808-5aac-43cd-8343-7454382443a5 --><h3>What information and self-care advice on eczema should I give?</h3><!-- end field ff5ae808-5aac-43cd-8343-7454382443a5 -->","summary":null,"htmlStringContent":"<!-- begin item fcf28aaa-c719-4ef8-a5b0-bedd4f2b9c5f --><!-- begin field 3f9336a1-1dc7-4e7f-bce9-ab6625c781c2 --><ul><li><strong>Provide information on atopic eczema.</strong><ul><li>Explain that eczema is a chronic illness characterized by flares, which can usually be controlled with appropriate treatment.</li><li>Provide information on recognizing:<ul><li>The early or prodromal signs and symptoms of a flare. Should this occur, advise immediate and aggressive treatment using an agreed <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/moderate-eczema/#management\">stepped-care plan</a>.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/background-information/complications/\">symptoms and signs</a> of eczema herpeticum, which is a medical emergency.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/infected-eczema/#management\">symptoms and signs</a> of infected eczema. </li></ul></li><li><strong>In children, </strong>inform parents/carers that:<ul><li>Eczema often improves with time. However, not all children will grow out of it, and it may get worse in teenage or adult life.</li><li>Children with atopic eczema can often develop asthma and/or allergic rhinitis and that sometimes food allergy is associated with atopic eczema, especially in very young children.</li></ul></li></ul></li><li><strong>P</strong><strong>rovide instructions on the <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/#usage-instructions\">correct use of emollients</a>, with clear demonstrations where appropriate. </strong>Also address any concerns regarding <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#prescribing-issues\">adverse effects of topical corticosteroids</a>.</li><li><strong>Give advice on measures to maintain the skin and reduce the risk of flares.</strong><ul><li>Encourage the frequent and liberal use of emollients, even during periods where the skin is clear.</li><li>Advise that where possible, they should avoid <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/diagnosis/identifying-trigger-factors/\">trigger factors</a> known to exacerbate eczema, such as certain clothing (they should avoid wearing synthetic fibres), soaps or detergents (they should use emollient substitutes), animals, and heat (they should keep rooms cool).<ul><li>House-dust mite avoidance strategies are generally not recommended as they are time consuming and of limited benefit.</li></ul></li><li>Advise that they should avoid scratching the eczema (if possible), and simply rub the area with their fingers to alleviate itch. Nails should be kept short, and anti-scratch mittens should be used in babies with eczema.</li></ul></li><li><strong>Also advise the person and/or their parents/carer that:</strong><ul><li>They should not alter their diet unless under specialist advice.<ul><li>Breastfeeding mothers of children with atopic eczema should not alter their diets unless under specialist advice. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/moderate-eczema/#breastfed-bottle-fed-infants\">Breastfed and bottle-fed infants</a> for more information.</li></ul></li><li>Complementary therapies are not recommended for the management of atopic eczema; a healthcare professional should be informed if these are used. Also advise that:<ul><li>Treatments such as homeopathic remedies, herbal medicine, massage, and food supplements (such as evening primrose oil) have not been adequately assessed in clinical trials.</li><li>All therapies that claim effectiveness (including natural remedies) may also have adverse effects.</li><li>Chinese herbal medicines have been associated with life-threatening adverse effects and have in some cases been contaminated with corticosteroids.</li><li>If they insists on using complementary therapies, they should continue using the emollients frequently and liberally, even when the skin is clear.</li></ul></li></ul></li><li><strong>Provide patient information leaflets and information on eczema support groups. </strong><ul><li>For example:<ul><li>The British Association of Dermatologists (BAD) has produced an information leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=69&itemtype=document.\" data-hyperlink-id=\"bb089354-5a11-4e9c-a46b-a8f70155a871\">Atopic Eczema</a>.</li><li>The National Eczema Society has <a href=\"http://www.eczema.org/factsheets\" data-hyperlink-id=\"0efe44f5-523f-4557-b75e-a8f70155a87a\">various factsheets</a> on eczema and treatments available on their website (<a href=\"http://www.eczema.org/\" data-hyperlink-id=\"e94b2624-0bf6-49e6-9d1d-a8f70155ab85\">www.eczema.org</a>).</li></ul></li><li>Where appropriate, advise on the <a href=\"https://apps.nhsbsa.nhs.uk/ppcwebsales/patient.do\" data-hyperlink-id=\"fd24ebf0-4d79-4ac4-8a4c-a8f70155ae8f\">NHS pre-payment certificate</a> (for people who pay prescription charges).</li></ul></li></ul><!-- end field 3f9336a1-1dc7-4e7f-bce9-ab6625c781c2 --><!-- end item fcf28aaa-c719-4ef8-a5b0-bedd4f2b9c5f -->","subChapters":[{"id":"1c42b143-a9a5-5467-a9d5-1e0761325dd7","slug":"breastfed-bottle-fed-infants","fullItemName":"Breastfed and bottle-fed infants:","depth":4,"htmlHeader":"<!-- begin field bcff3877-1929-4e53-9d2a-a716011c2fc4 --><h4>Breastfed and bottle-fed infants:</h4><!-- end field bcff3877-1929-4e53-9d2a-a716011c2fc4 -->","summary":null,"htmlStringContent":"<!-- begin item 63765d67-2c06-4947-9027-a716011c2f22 --><!-- begin field 2274db82-9a54-4c79-a073-a716011c2fc4 --><ul><li><strong>The mothers of breastfed infants in whom allergy is suspected to be the cause of moderate or severe eczema may require referral for dietary advice.</strong><ul><li>An allergen-specific exclusion diet may be considered; if this is not possible, the infant may be switched to a specialist formula milk (for example hypoallergenic hydrolyzed or amino acid-based products).</li><li>A 6–8 week trial of hydrolyzed protein formula milk or amino acid formula milk may be tried in bottle-fed children younger than 6 months of age with eczema that is not controlled by emollients and mild topical corticosteroids.<ul><li>Children who respond well to a change in their milk formula will require referral to a dietitian for further dietary advice to ensure healthy growth and development.</li><li>Children who do not respond are less likely to have a cows' milk allergy and should restart cow's milk, with monitoring of their eczema.</li></ul></li><li>Goat's milk and sheep's milk should not be used as they are nutritionally inadequate for human growth. Goat's milk, in any case, shares 95% of cross-reacting allergens with cows' milk.</li><li>Partially hydrolyzed formula milks are not suitable as the incomplete hydrolyzation process may be inadequate to completely eliminate all allergens.<ul><li>Soya protein diets can be used in children 6 months of age and older, following specialist advice. Such diets require careful balancing of nutritional content, and children who consume a soya based diet may be more likely to develop a peanut allergy.</li></ul></li><li>Advice should be sought from a dietitian with appropriate competencies.</li></ul></li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cows-milk-allergy-in-children/\">Cows&#39; milk protein allergy in children</a> for detailed information on this condition.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2011b</a>]</p><!-- end field 2274db82-9a54-4c79-a073-a716011c2fc4 --><!-- end item 63765d67-2c06-4947-9027-a716011c2f22 -->","subChapters":[]},{"id":"bc283a37-72d1-589c-9671-fe6d9da4ff21","slug":"basis-for-recommendation-ed9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f045fa7b-a2c4-4bfe-beaa-bb37c6748f1e --><h4>Basis for recommendation</h4><!-- end field f045fa7b-a2c4-4bfe-beaa-bb37c6748f1e -->","summary":null,"htmlStringContent":"<!-- begin item ed997e0a-a782-4971-bc44-85e3c72e41ed --><!-- begin field c7810ff1-4d3e-4f1b-afb7-05cdc712cce8 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<em> </em>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults. </p><p>These recommendations are also in line with those in <em>Caring for children and young people with atopic eczema: guidance for nurses</em> published by the Royal College of Nursing (RCN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>], <em>Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies </em>published by the<em> </em>American Academy of Dermatology (AAD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>], <em>Atopic eczema</em> published by the Primary Care Dermatology Society (PCDS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>], <em>S2k guideline on diagnosis and treatment of atopic dermatitis - short version </em>(a German guideline<em> </em>supported financially by the<em> </em>German Dermatology Society [DDG]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>], the <em>ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients </em>published by the European Task Force on Atopic Dermatitis (ETFAD) and European Academy of Dermatology and Venerology (EADV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>], and in review articles on atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Buddenkotte et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>]. </p><h5>Providing information on atopic eczema</h5><ul><li>Experts advise that:<ul><li>Providing information on the nature of atopic eczema, a comprehensive skin care plan, and access to good quality information and support is essential to allow families manage atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>].</li><li>The fear of adverse effects of topical corticosteroids should be recognized and addressed in order to improve adherence and avoid undertreatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>].</li></ul></li></ul><h5>Advice on measures to maintain the skin and reduce flares</h5><ul><li>Emollients are the first-line treatments for both acute flares of eczema and during remission [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>].</li><li>NICE states that treating dry skin (an early sign of a flare) with an emollient may prevent the flare worsening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<ul><li>Scratching is thought to be a major component of flare progression, as it physically damages the skin and can delay healing or facilitate infection. Emollients are believed to ease itching and thus may have a role in breaking the itch-scratch cycle [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Grimalt et al, 2007</a>].</li></ul></li><li>A Cochrane systematic review of 77 studies (n = 6603, mean age = 18.6 years, mean duration = 6.7 weeks) assessed the effects of moisturisers for eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">van Zuuren, 2017</a>]. The evidence suggested that most moisturisers showed some beneficial effects in prolonging time to flare, reducing the number of flares, and reducing the amount of topical corticosteroids needed to achieve similar reductions in eczema severity, producing better results when used with active treatment. However, there was no evidence that one moisturiser is better than another. </li></ul><h5>Advice on avoiding triggers</h5><ul><li>Avoiding scratching — the benefit of the short-term relief by scratching the skin is counteracted by a simultaneous damage of the epidermis, leading to increased transepidermal water loss and drying, which in turn results in a cycle of more itching and more scratching [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Buddenkotte et al, 2010</a>].</li><li>House-dust mite avoidance — NICE does not recommend house-dust mite elimination strategies for managing atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. Although people with atopic eczema are often sensitized to house dust mites [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014a</a>], there is no strong evidence that dust mite avoidance strategies are effective in treating or preventing atopic eczema:<ul><li>A systematic review and meta-analysis (n = 3040) assessed dust mite avoidance measures for the primary prevention of atopic dermatitis and found that they provided no benefit in the prevention of atopic dermatitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bremmer, 2015</a>].</li><li>A Cochrane systematic review (search date: August 2014) assessed the effects of house dust mite reduction and avoidance measures for the treatment of atopic eczema and was unable to determine clear implications to inform clinical practice, due to the low-quality evidence available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2015</a>].</li></ul></li><li>Irritants, temperature, humidity, pet removal, and stress — NICE found no evidence regarding avoidance of these triggers. However, experts recommend that if these triggers exacerbate eczema, they should be avoided, where possible [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BAD, 2017</a>].</li><li>Dietary modification:<ul><li>Evidence from a Cochrane systematic review (search date: March 2006) suggests that there is no benefit from milk and egg-free exclusion diets in people who do not have a known allergy to specific foods [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bath-Hextall et al, 2008</a>].</li><li>Expert opinion in the NICE guideline <em>Food allergy in children and young people. Diagnosis and assessment of food allergy in children and young people in primary care and community settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2011b</a>] is that if a food allergy is suspected, a healthcare professional with the appropriate competencies should take an allergy-focused clinical history tailored to the presenting symptoms and age of the child or young person. For more information, see the <a href=\"https://www.nice.org.uk/guidance/cg116/evidence/full-guideline-136470061\" data-hyperlink-id=\"5dd4cc09-c077-4712-b3bd-a8f7015a9f08\">full NICE guideline</a>.</li><li>Expert opinion in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>] on atopic eczema is that any dietary exclusion or elimination diets should be implemented and monitored by a specialist.</li><li>There is limited evidence to recommend the use of few-food diets, elemental diets, probiotic supplements, sodium cromoglicate, dietary exclusion in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lloyd-Lavery, 2016</a>], or dietary supplements with zinc, essential fatty acids, or vitamin B<sub>6 </sub>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bath-Hextall and Williams, 2007</a>] for the management of atopic eczema.</li></ul></li></ul><h5>Treatments not recommended</h5><ul><li>There is insufficient evidence to recommend complementary therapies (homeopathy, herbal medicine, massage, and food supplements) in the management of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>].</li><li>Limited evidence identified by CKS does not support the use of Chinese herbal medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Gu, 2013</a>], oral evening primrose oil [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bamford, 2013</a>], or borage oil [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bamford, 2013</a>] for the management of atopic eczema. </li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) warns that the phrases 'natural', 'herbal', and 'derived from plants' do not necessarily mean that the product is 'safe'. Herbal medicines, like other medicines, can have adverse effects. They can also interact with other medicines, resulting in reduced or enhanced effects of the other medicines. For further information, see <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Herbalmedicines/Usingherbalmedicinessafely/index.htm\" data-hyperlink-id=\"f4bf316e-bd59-4f50-a94a-a8f7015a9f4f\">www.mhra.gov.uk/safetyinformation</a> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">MHRA, 2012</a>].</li></ul><!-- end field c7810ff1-4d3e-4f1b-afb7-05cdc712cce8 --><!-- end item ed997e0a-a782-4971-bc44-85e3c72e41ed -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}